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Influenza virus represents a major public health concern worldwide after recent pandemics. To aid the
understanding and characterization of the virus in ever-increasing sample numbers, new research
techniques have been used, such as next-generation sequencing (NGS). The current article review used
Ovid MEDLINE and PubMed databases to conduct keyword searches and investigate the extent to which
published NGS high-throughput approaches have been implemented to influenza virus research in the
last 5 years, during which the increase in research funding for influenza studies has been coincidental
with a significant per-base cost reduction of sequencing. Through the current literature review, it is
evident that over the last 5 years, NGS techniques have been indeed applied to biological and clinical
samples at increasing rates following a wide variety of approaches. The rate of adoption is slower than
anticipated by most published studies, with three obstacles identified consistently by authors. These are
the lack of suitable downstream analytical capacity, the absence of established quality control compar-
ators, and the higher cost to comparable existing techniques.
Copyright © 2017 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza viruses are well-characterized members of the
Orthomyxoviridae family. Genomic subpopulation diversity and
new viral mutants emerge constantly because of the continued
viral genetic variation and antigenic modification in response to
many factors such as host immunity, ecological and environmental
factors, resulting in occasional pandemics and annual epidemics
(Zhirnov et al. 2009). Influenza remains a major threat on the global
agricultural and health care systems because of its continued po-
tential to cause pandemics worldwide and because of the
increasing number of seasonal infections impacting human and
economic health (Fischer et al. 2015). The high number of infections
and the recurrent seasonality mean that influenza is suitable for a
number of high-throughput molecular approaches in addition to
the basic virological techniques and clinical expertise to strengthen
global pandemic preparedness. In addition, the total and propor-
tional funding for influenza research (£39,139,703, 4.3% of total
infection research) increased in 2011e13 compared withis).
nian Bogor.
r. Production and hosting by Els1997e2010 (£126,643,152, 3.4% of all infection research), hence the
field is more likely able to afford the use of new and perhaps more
expensive technologies than studies of other infectious diseases
(Head et al. 2016). Coincidentally, the per-base cost of sequencing in
the same period has reduced by 92% from 0.52 to 0.04 USD per DNA
Mb (National Human Genome Research Institute, January
2010eJanuary 2015). Hence, according to our working hy-
pothesis, we expected to notice a steady increase in
published implementation examples as overall implementation
costs were reducing. In this brief report, we review the application
of high-throughput next-generation sequencing (NGS) in the study
of influenza and present the opportunities and challenges of
implementation as reported by the research community.
Currently, there are two major technologies used for influenza
genomic sequencing; the NGS and traditional Sanger sequencing
(Deng et al. 2015). The Sanger sequencing technology referred to as
first generation has been used for almost four decades and con-
tinues to be the standard reference method used. However, there is
a gradual yet notable shift away from this technique and in favor of
the use of newer technologies, namely the high-throughput NGS
(International Human Genome Consortium 2004). NGS also
referred to as deep sequencing or parallel sequencing (massively
parallel sequencing) provides high-speed multiplexing capabilitiesevier B.V. This is an open access article under the CC BY-NC-ND license (http://
R. Ali, et al156for high-throughput sample sequencing and enormous data vol-
umes of sequencing reads in one run (Barzon et al. 2011). Along
with the decreasing NGS costs, the applications of NGS techniques
within routine diagnostic settings are still evolving because of
recent and iterative developments in genome sequencing and
bioinformatics analyses (Fischer et al. 2015).
2. A Number of choices and challenges for NGS platforms
The common process of most NGS technologies is the initial
random fragmentation of templates, followed by an amplification
process using polymerase chain reaction target-specific primers,
resulting in many DNA copies that can be independently sequenced
(Metzker 2010). High-throughput sequencing platforms can be
divided into two broad groups depending on the template used.
The earliest platforms depend on the production of libraries of
clonally amplified templates. The recent arrival of single-molecule
sequencing platforms determines the sequence of single mole-
cules without amplification. Within these broad categories, there is
considerable variation in performancedincluding in throughput,
read length, and error ratedas well as in factors affecting usability,
such as cost and run time (Loman et al. 2012).
NGS technologies have a unique potential for the de novo
sequencing of large genomes, genomic markers screening, tran-
scriptome analysis, and several other applications (Bainbridge et al.
2006; Cheval et al. 2011; Greninger et al. 2010; Kuroda et al. 2010;
Nakamura et al. 2009; Pettersson et al. 2008; Satkoski et al. 2008;
Torres et al. 2008; Wheeler et al. 2008). However, the complexity
and large size of the sequencing data constitute one of the main
bioinformatics challenges of NGS data interpretation (Nowrousian
2010). The primary approach to NGS data analysis can be accom-
plished by using either one of three main types of tools, such
as general-purpose aligners, de novo assemblers, and short-read
aligners (Lin et al. 2014). NGS methods confer advantages over
other techniques such as highly specific reverse transcription-po-
lymerase chain reaction or less-sensitive traditional virological
methods for being able to produce unbiased sequencing without
prior knowledge of the presence or type of viral agents. This in turn
can potentially constitute them into the future gold standard tool
for viral genome discovery, especially in the case of recombinogenic
viruses, such as influenza (Bialasiewicz et al. 2014).
Through the current literature review, it is evident that over the
last 5 years, NGS techniques have been indeed applied to clinical
samples at increasing rates with some studies concentrating on the
detection of novel pathogens or pathogens at low detection levels.
Several variant strains and viruses have been successfully identi-
fied, such as the PIV4 subtype in late 2013(Alquezar-Planas et al.
2013), although it has to be noted that the numbers of unsuccess-
ful attempts are generally not mentioned, unclear, and/or very
difficult to even hazard a guess at. Other studies followed the
seasonal influenza infections in large population cohorts
(Nakamura et al. 2009), whereas influenza studies on animals have
also used NGS capabilities, such as sequences generated from lung
tissues of ferrets experimentally infected with influenza A/Califor-
nia/07/2009 (H1N1) (Lin et al. 2014). However, the overall numbers
of samples used per study vary widely, and the full implementation
of a high-throughput analytical pipeline remains difficult to ach-
ieve. The implementation challenges, solutions, and expectations of
the authors are also summarized.
3. Methods
Our research based on the Ovid MEDLINE database and the NCBI
PubMed databases was conducted with a total of 18 different
keywords in different combinations each time (initial conceptterms used: Influenza, next generation sequencing, and data not
shown). The literature search provided a wide variety of peer-
reviewed publications ranging in number from (10e18013). The
relevant article abstracts were manually selected corresponding to
publications where NGS was actually implemented as opposed to
being alluded to for future implementation. Then the exact
sequencing techniques used were determined, e.g. IlluminaTM
MiSeq/HiSeq NGS, RocheTM GS-FLXþ 454-pyrosequencing, and
others. Only two inclusion criteria were preselected, that is English
language and publication years from 2008 to 2015 inclusive.
4. Results
4.1. Influenza high-throughput DNA sequencing studies
Our research detected 64 research publications within the
publication years of 2008e2015. According to their methods,
almost all the studies used one or more of the following NGS
platforms (Roche-454 GS Junior/FLXþ, Ion Torrent/Proton/Personal
Genome Machine sequencing, and Illumina GAIIx/MiSeq/HISeq)
accompanied with a diverse and fragmented set of methods for the
upstream sample preparation and downstream bioinformatics
analyses.
Of the 64 research publications, 35 studies were performed
exclusively on humanmaterial (Fischer et al. 2015; Deng et al. 2015;
Kuroda et al. 2010; Cheval et al. 2011; Buggele et al. 2013; Depew
et al. 2013; Baum et al. 2010; Rutvisuttinunt et al. 2015; Frey et al.
2014; Farsani et al. 2015; Zhao et al. 2015; Rutvisuttinunt et al.
2013; Lee et al. 2013; Flaherty et al. 2012; Tellez-Sosa et al. 2013;
Borozan et al. 2013; Archer et al. 2012; Bidzhieva et al. 2014; Van
den Hoecke et al. 2015; Leung et al. 2013; Watson et al. 2013;
Harismendy et al. 2009; Zhou et al. 2014; Kuroda et al. 2015;
Burnham et al. 2015; Varble et al. 2014; Tan et al. 2014; Saira et al.
2013; Selleri, 2013; Swaminathan et al. 2013; Xiao et al. 2013;
Power et al. 2012; Whitehead et al. 2012; Yasugi et al. 2012), 10
on animal material (Lin et al. 2014; Jakhesara et al. 2014; Van Borm
et al. 2012; Dugan et al. 2011; Clavijo et al. 2013; Leon et al. 2013;
Lange et al. 2013; Iqbal et al. 2014; Peng et al. 2011; Wang et al.
2012), seven on both animal and human materials (Yu et al. 2014;
Jonges et al. 2014; Kampmann et al. 2011; Peng et al. 2014;
Karlsson et al. 2013; Sikora et al. 2014; Ren et al. 2013), two on
plasmid-derived material (Depew et al. 2013; Wu et al. 2014), and
10 reviewed technical and bioinformatics aspects (Barzon et al.
2011; Metzker 2010; Qui~nones-Mateu et al. 2014; Park et al. 2013;
Dugan et al. 2012; MacLean et al. 2009; Radford et al. 2012;
Ansorge 2009; Shendure and Ji 2008; Tsai and Chen 2011). The
number of samples used per study varied widely, with most studies
reporting numbers in the low hundreds and less than 10 reporting
the use of more than 1000 samples.
4.2. Challenges, opportunities, and solutions of NGS
implementation
From the aforementioned, it becomes immediately obvious that
the initial NGS applications in the field of influenza research are not
reflective of a consistent, universally applied, and true high-
throughput approach. Indeed, the picture obtained throughout is
one reflecting the initial stages for the adoption of a technical
innovation. The challenges mentioned by the various authors are
summarized in the Table. The generation of high volumes of data
requiring sophisticated downstream bioinformatics analyses is
mentioned as the primary challenge for the adoption of the method
and interpretation of the NGS outputs. In fact, this single challenge
is mentioned in more than two-thirds of all the identified studies.
The lack of large-scale validation of NGS outputs with regard to
costs and data complexity is challenging and perhaps not feasible
for individual research groups to achieve, hence its function as an
Table. A summary of the most commonly mentioned challenges, solutions, and implementation potentials for next-generation sequencing on the field of influenza virus
research
Challenges References
The need for complicated bioinformatics analysis as NGS delivers
high volumes of raw reads
Deng et al. (2015), Cheval et al. (2011), Torres et al. (2008), Nowrousian (2010),
Alquezar-Planas et al. (2013), Kampmann et al. (2011), Frey et al. (2014),
Zhao et al. (2015), Lee et al. (2013), Archer et al. (2012), Bidzhieva et al. (2014),
Kuroda et al. (2015), Iqbal et al. (2014), MacLean et al. (2009), Radford et al. (2012),
Peng et al. (2014), Peng et al. (2011)
The high cost and less availability of NGS equipment Fischer et al. (2015), Deng et al. (2015), Ansorge (2009), Zhao et al. (2015),
MacLean et al. (2009)
Requirements for clinical assay validation Fischer et al. (2015), Kampmann et al. (2011), Rutvisuttinunt et al. (2015),
Frey et al. (2014)
Solutions References
Clinical validation of NGS Fischer et al. (2015)
Development of an automated assembly and analysis pipeline can
make the bioinformatics analysis of transferring raw reads to
the specific genomic identification more efficient
Alquezar-Planas et al. (2013), Frey et al. (2014)
Batching and multiplexing samples in single sequencing runs,
while maintaining error rates and relative cost low
Ansorge (2009), Lee et al. (2013)
Implementation References
Allows the full genome sequencing of influenza A viruses in a single run Deng et al. (2015), Torres et al. (2008), Yu et al. (2014), Farsani et al. (2015),
Lee et al. (2013), Tellez-Sosa et al. (2013), Archer et al. (2012), Zhou et al. (2014),
Van Borm et al. (2012), Quail et al. (2012), Selleri (2013)
Generate an impressive amount of sequence information in a
short time frame and high speed
Alquezar-Planas et al. (2013), Kampmann et al. (2011), Rutvisuttinunt et al. (2015),
Farsani et al. (2015), Rutvisuttinunt et al. (2013), Flaherty et al. (2012),
Tellez-Sosa et al. (2013), Archer et al. (2012), Bidzhieva et al. (2014),
Leung et al. (2013), Watson et al. (2013), Kuroda et al. (2015), MacLean et al. (2009),
Radford et al. (2012)
Has the potential to detect known and unknown pathogens
(viruses, bacteria, fungi, and parasites), novel viruses in heterogeneous
populations in a single application
Fischer et al. (2015), Nowrousian (2010), Lin et al. (2014), Alquezar-Planas et al. (2013),
Ansorge (2009), Yu et al. (2014), Kampmann et al. (2011), Rutvisuttinunt et al. (2015),
Frey et al. (2014), Van den Hoecke et al. (2015), Kuroda et al. (2015)
NGS ¼ next-generation sequencing
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ond most popular challenge, followed by the high cost of the new
technique compared with existing traditional methods.
The solutions suggested to overcome these issues were much
more diverse and fragmented in nature. A large number of authors
stressed the need for the development of an automated assembly
and development software pipeline, making the whole NGS
downstream analyses more efficient and reliable. Although most
authors appreciate the production of a series of standard operating
procedures, very few are willing to test (individually or institu-
tionally) and compare the different recommended standard oper-
ating procedures. The ability tomatch andmultiplex the samples in
single sequencing runs is one of the solutions implemented to
create cost efficiencies according to the manufacturers'
recommendations.
The opportunities that NGS provides to research are evident to
all authors. The ability to produce a number of complete influenza
genomes in a single run at high resolution and the potential to
detect heterogeneous populations in a single application are clearly
outlined. The production of considerably larger amounts of
sequence information in a short time frame and high speed as
compared with traditional molecular methods was also welcome.
5. Discussion
In the last few years, high-throughput NGS technologies have
become more widely available, and they are under continuous
improvement and development. NGS has already been used in
several projects, in metagenomics, whole genome sequencing, RNA
sequencing, and small RNA discovery (Barzon et al. 2011). These
technologies confer advantages over older methods, including
single-molecule sequencing, high-throughput and increased
quantity of sequencing data, while avoiding the necessity for
cloning individual DNA fragments (Ansorge 2009).
However, NGS technologies share common features that still
limit their use. Through the current search, these have beenidentified as being the generation of high-throughput data that
require substantial computational resources for their subsequent
analyses and quality control, the high comparative cost of
sequencing using NGS, and the availability of suitable equipment
(Deng et al. 2015; Metzker 2010). As such, the complete replace-
ment of the Sanger-based methods is yet unlikely, until the afore-
mentioned barriers are addressed successfully. The NGS cost per
run and the cost per sample has already decreased substantially,
and higher multiplexing approaches exert further pressure
toward this direction (Qui~nones-Mateu et al. 2014).
According to our current observations, the adoption of NGS
sequencing in influenza research seems to correlate well with
Buxton's law, where “it is always too early [for rigorous evaluation]
until, unfortunately, it's suddenly too late (Buxton and Drummond
1987).” The initial adopters of NGS are unable or reluctant to apply
formative assessment of the different existing technologies, in part
because the technologies themselves are still under development.
However, as the clinical introduction of NGS starts to materialize,
the number of NGS adopters increases and the technique becomes
more familiar and integrated within organized facilities, and the
completion of an evidence-based assessment will be even more
difficult to materialize.
In practice, the current NGS applications are very similar to most
newly implemented innovations, composed of a hard core of fixed
techniques (e.g. library preparation) with a soft periphery of fea-
tures (e.g. bioinformatics analyses). The existence of this soft pe-
riphery means that the distribution of risk and benefits for the
adopters is not entirely fixed as NGS can be implemented in a va-
riety of ways that are not fully clarified by the existing peer-
reviewed literature (Ilinca et al. 2012). The uncertainty surrounding
some of the implementations and outputs would be expected to
still generate a multitude of different claims and adoption
pathways.
Having said that, NGS is a very successful platform for viral
research studies as it has already led to the discovery of novel vi-
ruses and their association of pathogenesis in diseases (Qui~nones-
R. Ali, et al158Mateu et al. 2014). Hence, it is widely expected that these tech-
nologies will be applied in routine clinical virology laboratories for
nearly all viral pathogens including influenza viruses in the not-so-
distant future (Gibson et al. 2014; Swenson et al. 2011; Kagan et al.
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